Proactiveinvestors Interviews Bob Proulx on FDA Fast Track Status for MagSense® Imaging

Proactiveinvestors Interviews Bob Proulx on FDA Fast Track Status for MagSense® Imaging

Proactiveinvestors interviews Bob Proulx on what FDA’s designation of MagSense® imaging as a “breakthrough device” means for the company and its investors:
https://youtu.be/X4HLKyIl6Zo

Related Articles

Imagion AGM Business Update

MELBOURNE – Imagion Biosystems (Company, ASX: IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to provide shareholders

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.